CANbridge Life Sciences Ltd. is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.
- 2016-08-11 CANBRIDGE SIGNS AGREEMENT WITH BOEHRINGER INGELHEIM TO MANUFACTURE INHIBITORY ANTIBODY,CAN-017, FOR ESOPHAGEAL SQUAMOUS CELL CANCER
- 2016-07-26 CANBRIDGE’S CAN-008 APPROVED FOR PHASE I/II TRIAL IN NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME IN TAIWAN
- 2016-07-05 CANBRIDGE APPOINTS DR. HUAI ZHONG HU AS VICE PRESIDENT OF PRECLINICAL DEVELOPMENT
Addr: Suite 303A, Building E, Wangjing Pioneer Park,
No. 2 LizeZhongEr Road, Chaoyang District, Beijing, China